Five-year follow-up results from the Phase 3 Study 309/KEYNOTE-775, presented at ESMO 2025, confirm that lenvatinib plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback